In repeat-dose rodent studies (14-day), REXD-541 was well-tolerated up to 200 mg/kg. No observed adverse effect level (NOAEL) was established at 100 mg/kg. The primary findings at high doses included mild, reversible elevations in liver transaminases (ALT/AST) and transient GI distress. No genotoxicity was detected in Ames or micronucleus assays.
REXD-541 represents a promising, though early, candidate in the small-molecule drug pipeline. Its favorable preclinical efficacy and safety suggest it may soon enter first-in-human trials. Researchers and investors should watch for peer-reviewed disclosures and an upcoming investigational new drug (IND) application. rexd-541
Once you provide a bit more context, I can try to locate the specific information you need. No genotoxicity was detected in Ames or micronucleus assays
I am not aware of a specific, widely recognized scientific paper or standard document with the identifier in my training data (up to my knowledge cutoff). REXD-541 faces typical early-stage hurdles:
REXD-541 faces typical early-stage hurdles: